UNSPSC 51283910: Sulfadimethazine or sulfadimidine or sulfamidine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C12H14N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48U51W007F, chemically known as 4,6-dimethylsulfadiazine but generally known as sulfadimidine, which bears US NIH Compound Identifier 5327. European Medicines Agency schedules Sulfadimidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10699MIG.

World Health Organization schedules sulfadimidine in its Anatomical Therapeutic Chemical (ATC) Classification. SULFADIMIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C.

UNSPSC 51283910 Sulfadimethazine or sulfadimidine or sulfamidine is a Commodity code that bears little resemblance to the actual state and local procurement activity tagged under it. The recent opportunities solicited under this code—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical and first aid supplies, and generic multi-source pharmaceuticals and OTC products—do not involve sulfadimethazine or related sulfonamide compounds, which are narrow-spectrum antibiotics used in veterinary and niche human applications. State and local governments are instead procuring a much broader range of emergency response pharmaceuticals, OTC products, and pharmacy program support services through this code. The issuing bodies include counties (Seminole County, Florida), cities (Tampa), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP).

Recent activity spans Florida, Texas, and Minnesota across a mix of sourcing mechanisms. Seminole County posted an IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (Solicitation IFB60459723LAS); the Texas HHS Commission issued an RFI on direct-to-manufacturer prescriptions with a response deadline of April 3, 2026 (HHS0017013); the City of Tampa released an IFB for medical and first aid supplies with a response deadline of March 13, 2026 (26P00145), designated as a sheltered market opportunity for certified Small Local Business Enterprises with an estimated contract value of $700,000; and MMCAP released an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026 (S1070000015802), serving state and local facilities across Minnesota and Oregon through authorized wholesalers. The code shows no relevant recent activity aligned with its nominal pharmaceutical scope—vendors evaluating this code should verify directly with issuing bodies whether future opportunities will reflect the code's stated definition or continue to source unrelated health products and services.